Navigation Links
Glowing Substance Lights Up Cancer in Mice
Date:12/8/2008

Fluorescent compound sticks to diseased cells, making them easier to spot, study says

MONDAY, Dec. 8 (HealthDay News) -- A substance that glows and sticks to viable cancer cells, making them easy for doctors to spot, has been successfully tested in mice, researchers report.

The man-made compound, a combination of the breast cancer drug Herceptin and a fluorescent molecule called BODIPY, binds to the HER2 protein contained on the surface of some breast cancer cells. It only glows, or fluoresces, when inside living cells -- an improvement from most fluorescent imaging compounds that always glow and make it difficult for doctors to tell viable tumor cells from normal tissue or dead or damaged tumor cells.

The findings, made by researchers at the U.S. National Cancer Institute, were published online Dec. 7 in Nature Medicine.

"Imaging compounds designed by our concept may have applications in the clinic," lead researcher Dr. Hisataka Kobayashi of the Molecular Imaging Program of NCI's Center for Cancer Research, said in a news release issued by the institute. "These compounds may allow clinicians to monitor a patient's response to cancer therapy by allowing them to visualize whether a drug hits its target and whether hitting the target leads to shrinkage of the tumor. With additional research and extensive testing in humans, these compounds may also be adapted for use in endoscopy procedures and for use as a surgical aid to improve removal of tumors."

The compound should be able to be engineered to target specific types of cancer cells.

"Our design concept is very versatile and can be used to detect many types of cancer," Kobayashi said. "Unlike other activatable fluorescent compounds, our compound consists of a targeting agent and a fluorescing agent that act independently. We can target the fluorescing agent to different types of cancer cells by using any antibody or molecule that is internalized by the targeted cells after it binds to the cells' surface proteins."

In their study, the team injected either their compound or one that always fluoresces in mice with HER2-positive breast cancer tumors that had spread to their lungs. A day later, the "activatable" compound was found only in lung tumors, while the "always on" one glowed on lung tumors, normal lung tissue and the heart.

The findings showed the compound was 99 percent accurate in tumor detection for HER2-positive tumors, while the "always on" control was accurate less than 85 percent of the time.

In another experiment, the researchers re-engineered the compound so it successfully detected live ovarian cancer cells that had spread to the tissue lining the walls of the abdomen in mice.

More information

The U.S. National Cancer Institute has more about breast cancer.



-- Kevin McKeever



SOURCE: U.S. National Institutes of Health, news release, Dec. 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Mailman School of Public Health study examines link between racial discrimination and substance use
2. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
3. Inflammatory Substance May Boost Eye Trouble
4. Research examines connection between substance abuse and violence
5. L.A. Author, TV Personality and Substance Abuse Specialist Discusses Struggle to Break Bad-girl Syndrome Oct. 26-28 in Baltimore
6. Gauging parent knowledge about teens substance use
7. Substance abuse practitioners ask what is recovery?
8. One-Third of Popular Songs Refer to Substance Abuse
9. AAPM statement on DEA ruling allowing multiple prescriptions for controlled substances
10. Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility
11. PSU $5.7 million grant to help families and youth avoid substance abuse, behavior problems
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Glowing Substance Lights Up Cancer  in Mice
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: